REGENXBIO Inc. reported its financial results for the first quarter ended March 31, 2025, on May 12, 2025. Cash, cash equivalents, and marketable securities increased to $272.7 million as of March 31, 2025, primarily due to the $110.0 million upfront payment from the Nippon Shinyaku partnership.
Total revenues for the first quarter of 2025 significantly increased to $89.0 million, compared to $15.6 million for the same period in 2024. This increase was largely driven by $71.8 million of license and service revenue recognized under the Nippon Shinyaku collaboration.
The company reported a net income of $6.1 million, or $0.12 per basic and diluted share, for Q1 2025, a substantial improvement from a net loss of $63.3 million, or $1.38 per share, in Q1 2024. REGENXBIO expects its cash position to fund operations into the second half of 2026, excluding potential PRV monetization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.